Elaprace IV infusion 6mg, containing Idursulfase (genetically recombinant), is manufactured by Sanofi. This injectable drug, with YJ code 3959413A1029 and standard 6mg x 3mL x 1 bottle, is used as an enzyme replacement therapy to treat Hunter syndrome (Mucopolysaccharidosis II or MPS II).
Elaprace IV infusion 6mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →